GlassScriptPhysician profile
Diana Bytyqi
NPI 1336665009
$52,618.98
in general payments reported to CMS, 2019-2025
35 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $452 · 2022: $16K · 2023: $13K · 2024: $5,637 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Travel and Lodging: $4,647 · Food and Beverage: $4,119 · Education: $41.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,726.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,826.26 |
| Travel and Lodging | $4,647.23 |
| Food and Beverage | $4,118.84 |
| Education | $41.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $32,413.88 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $17,105.84 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Lilly USA, LLC | $436.37 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $393.54 | 2021-2025 | Evenity, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.29 | 2021-2025 | Jardiance |
| Abbott Laboratories | $224.86 | 2021-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $145.91 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Antares Pharma, INC. | $135.20 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Medtronic, INC. | $123.99 | 2021-2025 | Minimed 780g |
| Amneal Pharmaceuticals LLC | $122.56 | 2021-2025 | Unithroid |
| Radius Health, INC. | $119.48 | 2022-2024 | Tymlos |
| Abbvie INC. | $104.04 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.06 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $90.97 | 2021-2025 | |
| Cequr Corporation | $88.13 | 2022-2025 | Cequr Simplicity |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $68.58 | 2022-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $68.36 | 2021-2023 | Farxiga |
| Kyowa Kirin, INC. | $55.80 | 2023-2025 | Crysvita |
| Novartis Pharmaceuticals Corporation | $52.96 | 2025 | |
| Ibsa Pharma INC. | $48.17 | 2023-2025 | Tirosint, Tirosint, Licart |
| Halozyme INC | $44.83 | 2023 | |
| Merck Sharp & Dohme LLC | $41.81 | 2022-2023 | Steglujan, Segluromet, Steglatro |
| Tandem Diabetes Care, INC. | $33.94 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Acella Pharmaceuticals, LLC | $30.74 | 2023-2025 | NP Thyroid 60 |
| Clarus Therapeutics INC. | $23.97 | 2021 | |
| Corcept Therapeutics | $21.85 | 2022 | |
| Sequel Med Tech, LLC | $20.03 | 2025 | Twiist |
| Beta Bionics, INC. | $19.03 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Lifescan, INC. | $18.56 | 2022 | |
| Mannkind Corporation | $18.33 | 2023 | Afrezza |
| Currax Pharmaceuticals LLC | $17.84 | 2023 | Contrave |
| Amarin Pharma, INC. | $16.70 | 2021 | |
| Almatica Pharma LLC | $15.36 | 2025 | Teriparatide |
| Madrigal Pharmaceuticals | $14.45 | 2025 | Rezdiffra |
| Averitas Pharma INC. | $13.55 | 2025 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Bytyqi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.